The Claim
In adults with type 2 diabetes, once-weekly exenatide at a dose of 2 mg reduces the risk of all-cause mortality by 14% (hazard ratio 0.86, 95% CI 0.77–0.97) over a median follow-up of 3.2 years, based on data from a randomized controlled trial of 14,752 participants, with a more pronounced effect observed in individuals without preexisting heart failure, where mortality risk is reduced by 21%, supporting the role of GLP-1 receptor agonists in cardiovascular risk reduction strategies.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A weekly diabetes shot called exenatide may help people with type 2 diabetes live longer, especially if they don’t already have heart failure.
See the scientific wording
Once-weekly exenatide at a dose of 2 mg reduces the risk of all-cause death by 14% in adults with type 2 diabetes, with a hazard ratio of 0.86 (95% CI 0.77–0.97), based on data from a randomized controlled trial involving 14,752 participants followed for a median of 3.2 years. This effect is driven primarily by benefits in patients without preexisting heart failure, where mortality risk is reduced by 21%. The finding supports the use of GLP-1 receptor agonists as part of cardiovascular risk reduction strategies in type 2 diabetes.
What the research says
1 studyThe study tested the same drug and dose as claimed and found it lowered the risk of death, especially in people without heart failure, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.